Polyclonal anti-whole cell IgY passive immunotherapy shields against P. aeruginosa-induced acute pneumonia and burn wound infections in murine models

[1]  J. Stålberg,et al.  Intravenous anti-P. aeruginosa IgY-antibodies do not decrease pulmonary bacterial concentrations in a porcine model of ventilator-associated pneumonia , 2022, Innate immunity.

[2]  N. Høiby,et al.  Immune Response to Biofilm Growing Pulmonary Pseudomonas aeruginosa Infection , 2022, Biomedicines.

[3]  A. M. Rodgers,et al.  Pseudomonas aeruginosa: Recent Advances in Vaccine Development , 2022, Vaccines.

[4]  M. Zimic,et al.  Preclinical Assessment of IgY Antibodies Against Recombinant SARS-CoV-2 RBD Protein for Prophylaxis and Post-Infection Treatment of COVID-19 , 2022, Frontiers in Immunology.

[5]  Michael J. Rybak,et al.  Therapeutic Strategies for Emerging Multidrug-Resistant Pseudomonas aeruginosa , 2022, Infectious Diseases and Therapy.

[6]  J. Dye,et al.  Egg-Derived Anti-SARS-CoV-2 Immunoglobulin Y (IgY) With Broad Variant Activity as Intranasal Prophylaxis Against COVID-19 , 2022, Frontiers in Immunology.

[7]  G. Irajian,et al.  Passive immunization with anti- chimeric protein PilQ/PilA -DSL region IgY does not protect against mortality associated with Pseudomonas aeruginosa sepsis in a rabbit model. , 2021, Molecular immunology.

[8]  X. Shen,et al.  Egg yolk immunoglobulin (IgY) targeting SARS‐CoV‐2 S1 as potential virus entry blocker , 2021, Journal of applied microbiology.

[9]  Cuicui Ma,et al.  A novel inactivated whole-cell Pseudomonas aeruginosa vaccine that acts through the cGAS-STING pathway , 2021, Signal Transduction and Targeted Therapy.

[10]  Zeling Xu,et al.  Molecular Mechanisms Underlying the Regulation of Biofilm Formation and Swimming Motility by FleS/FleR in Pseudomonas aeruginosa , 2021, Frontiers in Microbiology.

[11]  S. M. Mousavi Gargari,et al.  Anti-flagellin IgY antibodies protect against Pseudomonas aeruginosa infection in both acute pneumonia and burn wound murine models in a non-type-specific mode. , 2021, Molecular immunology.

[12]  S. Sousa,et al.  Immunization and Immunotherapy Approaches against Pseudomonas aeruginosa and Burkholderia cepacia Complex Infections , 2021, Vaccines.

[13]  S. McClean,et al.  Pseudomonas aeruginosa: An Audacious Pathogen with an Adaptable Arsenal of Virulence Factors , 2021, International journal of molecular sciences.

[14]  N. Høiby,et al.  Azithromycin potentiates avian IgY effect against Pseudomonas aeruginosa in a murine pulmonary infection model. , 2020, International journal of antimicrobial agents.

[15]  S. M. Gargari,et al.  Protective effects of egg yolk immunoglobulins (IgYs) developed against recombinant immunogens CtxB, OmpW and TcpA on infant mice infected with Vibrio cholerae. , 2020, International immunopharmacology.

[16]  Dima Ibrahim,et al.  Current choices of antibiotic treatment for Pseudomonas aeruginosa infections , 2020, Current opinion in infectious diseases.

[17]  H. Goli,et al.  Prevalence of multi-drug resistant (MDR) and extensively drug-resistant (XDR) phenotypes of Pseudomonas aeruginosa and Acinetobacter baumannii isolated in clinical samples from Northeast of Iran , 2020, BMC Research Notes.

[18]  S. M. Mousavi Gargari,et al.  Protective Efficacy of the OprF/OprI/PcrV Recombinant Chimeric Protein Against Pseudomonas aeruginosa in the Burned BALB/c Mouse Model , 2020, Infection and drug resistance.

[19]  F. Norouzi,et al.  Immunotherapy with IgY Antibodies toward Outer Membrane Protein F Protects Burned Mice against Pseudomonas aeruginosa Infection , 2020, Journal of immunology research.

[20]  W. Lim,et al.  Co-infections in people with COVID-19: a systematic review and meta-analysis , 2020, Journal of Infection.

[21]  Z. Nawaz,et al.  Association of biofilm formation with multi drug resistance in clinical isolates of Pseudomonas aeruginosa , 2020, EXCLI journal.

[22]  H. Terzolo,et al.  IgY-technology (egg yolk antibodies) in human medicine: A review of patents and clinical trials. , 2020, International immunopharmacology.

[23]  A. Ardebili,et al.  Evaluation of antimicrobial resistance, biofilm forming potential, and the presence of biofilm-related genes among clinical isolates of Pseudomonas aeruginosa , 2020, BMC Research Notes.

[24]  J. Edwards,et al.  Antimicrobial-resistant pathogens associated with adult healthcare-associated infections: Summary of data reported to the National Healthcare Safety Network, 2015–2017 , 2019, Infection Control & Hospital Epidemiology.

[25]  M. Bandehpour,et al.  In Silico Design and Evaluation of Acinetobacter baumannii Outer Membrane Protein a Antigenic Peptides As Vaccine Candidate in Immunized Mice. , 2019, Iranian journal of allergy, asthma, and immunology.

[26]  F. Norouzi,et al.  Anti-PcrV IgY antibodies protect against Pseudomonas aeruginosa infection in both acute pneumonia and burn wound models. , 2019, Molecular immunology.

[27]  A. Oliver,et al.  Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Infections , 2019, Clinical Microbiology Reviews.

[28]  A. Larsson,et al.  Inhalation of specific anti-Pseudomonas aeruginosa IgY antibodies transiently decreases P. aeruginosa colonization of the airway in mechanically ventilated piglets , 2019, Intensive Care Medicine Experimental.

[29]  M. Nilles,et al.  Zika Virus-Specific IgY Results Are Therapeutic Following a Lethal Zika Virus Challenge without Inducing Antibody-Dependent Enhancement , 2019, Viruses.

[30]  M. Ouellette,et al.  Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. , 2017, The Lancet. Infectious diseases.

[31]  N. Høiby,et al.  Biofilms and host response – helpful or harmful , 2017, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[32]  G. Irajian,et al.  Flagellin and pilin immunization against multi-drug resistant Pseudomonas aeruginosa protects mice in the burn wound sepsis model. , 2016, Immunology letters.

[33]  G. Irajian,et al.  Immunogenicity and protective efficacy of Pseudomonas aeruginosa type a and b flagellin vaccines in a burned mouse model. , 2016, Molecular immunology.

[34]  G. Irajian,et al.  Immunogenicity of Pseudomonas aeruginosa recombinant b-type fagellin as a vaccine candidate: Protective efficacy in a murine burn wound sepsis model. , 2016, Burns : journal of the International Society for Burn Injuries.

[35]  N. Høiby,et al.  Anti-Pseudomonas aeruginosa IgY antibodies promote bacterial opsonization and augment the phagocytic activity of polymorphonuclear neutrophils , 2016, Human vaccines & immunotherapeutics.

[36]  M. Mousavi,et al.  Active Immunization with Recombinant PilA protein Protects Against Pseudomonas aeruginosa Infection in a Mouse Burn Wound Model. , 2015, Journal of microbiology and biotechnology.

[37]  N. Høiby,et al.  Anti-Pseudomonas aeruginosa IgY Antibodies Induce Specific Bacterial Aggregation and Internalization in Human Polymorphonuclear Neutrophils , 2015, Infection and Immunity.

[38]  T. Sawa,et al.  Anti-PcrV antibody strategies against virulent Pseudomonas aeruginosa , 2014, Human vaccines & immunotherapeutics.

[39]  M. Soudi,et al.  Optimization of tetrazolium salt assay for Pseudomonas aeruginosa biofilm using microtiter plate method. , 2014, Journal of microbiological methods.

[40]  N. Høiby,et al.  Anti-Pseudomonas aeruginosa IgY antibodies augment bacterial clearance in a murine pneumonia model. , 2014, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[41]  J. Zhu,et al.  Protective effect of an egg yolk‐derived immunoglobulin (IgY) against Prevotella intermedia‐mediated gingivitis , 2014, Journal of applied microbiology.

[42]  J. Goldberg,et al.  Vaccines for Pseudomonas aeruginosa: a long and winding road , 2014, Expert review of vaccines.

[43]  Y. Kodama,et al.  Oral passive IgY-based immunotherapeutics , 2013, Human vaccines & immunotherapeutics.

[44]  J. Šimůnek,et al.  Optimized Protocol of Chicken Antibody (IgY) Purification Providing Electrophoretically Homogenous Preparations , 2013, International Journal of Electrochemical Science.

[45]  Swe Swe Myint,et al.  Randomized placebo-controlled clinical trial of immunoglobulin Y as adjunct to standard supportive therapy for rotavirus-associated diarrhea among pediatric patients. , 2012, Vaccine.

[46]  E. Jaffee,et al.  Whole cell vaccines--past progress and future strategies. , 2012, Seminars in oncology.

[47]  Guoying Liu,et al.  CpG oligodeoxynucleotide and montanide ISA 206 adjuvant combination augments the immune responses of a recombinant FMDV vaccine in cattle. , 2011, Vaccine.

[48]  M. McConnell,et al.  Active and passive immunization against Acinetobacter baumannii using an inactivated whole cell vaccine. , 2010, Vaccine.

[49]  H. Lei,et al.  Passive protection effect of chicken egg yolk immunoglobulins on enterovirus 71 infected mice , 2010, Vaccine.

[50]  S. Meenatchisundaram,et al.  Chicken Egg Yolk Antibodies (IgY) as an Alternative to Mammalian Antibodies , 2010 .

[51]  A. Larsson,et al.  Good effect of IgY against Pseudomonas aeruginosa infections in cystic fibrosis patients , 2008, Pediatric pulmonology.

[52]  S. Diamond,et al.  Neutrophil Isolation Protocol , 2008, Journal of visualized experiments : JoVE.

[53]  D. Zillikens,et al.  Binding of avian IgY to type VII collagen does not activate complement and leucocytes and fails to induce subepidermal blistering in mice , 2008, The British journal of dermatology.

[54]  D. Carlander,et al.  More than 10 years' continuous oral treatment with specific immunoglobulin Y for the prevention of Pseudomonas aeruginosa infections: a case report. , 2007, Journal of medicinal food.

[55]  J. Goldberg,et al.  Intranasal immunization with heterologously expressed polysaccharide protects against multiple Pseudomonas aeruginosa infections , 2007, Proceedings of the National Academy of Sciences of the United States of America.

[56]  A. Cripps,et al.  Safety and Immunogenicity of an Oral Inactivated Whole-Cell Pseudomonas aeruginosa Vaccine Administered to Healthy Human Subjects , 2006, Infection and Immunity.

[57]  S. Lory,et al.  Role of Motility and Flagellin Glycosylation in the Pathogenesis of Pseudomonas aeruginosa Burn Wound Infections , 2005, Infection and Immunity.

[58]  Y. Carmeli,et al.  Antibodies raised against N'-terminal Pseudomonas aeruginosa flagellin prevent mortality in lethal murine models of infection. , 2005, International journal of molecular medicine.

[59]  T. Sawa,et al.  Passive anti-PcrV treatment protects burned mice against Pseudomonas aeruginosa challenge. , 2005, Burns : journal of the International Society for Burn Injuries.

[60]  S. Logsetty,et al.  Pseudomonas infections in the thermally injured patient. , 2004, Burns : journal of the International Society for Burn Injuries.

[61]  S. Davis,et al.  A Wound‐Isolated Pseudomonas aeruginosa Grows a Biofilm In Vitro Within 10 Hours and Is Visualized by Light Microscopy , 2003, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[62]  D. Carlander,et al.  Oral administration of specific yolk antibodies (IgY) may prevent Pseudomonas aeruginosa infections in patients with cystic fibrosis: A phase I feasibility study , 2003, Pediatric pulmonology.

[63]  H. Sunwoo,et al.  In vitro studies of chicken egg yolk antibody (IgY) against Salmonella enteritidis and Salmonella typhimurium. , 2002, Poultry science.

[64]  N. Shime,et al.  Therapeutic Administration of Anti-PcrV F(ab′)2 in Sepsis Associated with Pseudomonas aeruginosa1 , 2001, The Journal of Immunology.

[65]  A. Neely,et al.  PcrV Immunization Enhances Survival of Burned Pseudomonas aeruginosa-Infected Mice , 2001, Infection and Immunity.

[66]  Pan‐Chyr Yang,et al.  Persistence of a Multidrug-ResistantPseudomonas aeruginosa Clone in an Intensive Care Burn Unit , 1998, Journal of Clinical Microbiology.

[67]  J. Sjöquist,et al.  Use of chicken antibodies in enzyme immunoassays to avoid interference by rheumatoid factors. , 1991, Clinical chemistry.

[68]  K. Irie,et al.  Inhibitory activity on bacterial motility and in vivo protective activity of human monoclonal antibodies against flagella of Pseudomonas aeruginosa , 1991, Infection and immunity.

[69]  M. Brett,et al.  Serum IgA antibodies against Pseudomonas aeruginosa in cystic fibrosis. , 1990, Archives of disease in childhood.

[70]  P. McDonald,et al.  Enhanced susceptibility of gram-negative bacteria to phagocytic killing by human polymorphonuclear leucocytes after brief exposure to aztreonam. , 1988, The Journal of antimicrobial chemotherapy.

[71]  R. Craven,et al.  Loss of virulence associated with absence of flagellum in an isogenic mutant of Pseudomonas aeruginosa in the burned-mouse model , 1982, Infection and immunity.

[72]  Eugene Rosenberg,et al.  Adherence of bacteria to hydrocarbons: A simple method for measuring cell‐surface hydrophobicity , 1980 .

[73]  Xiaoyu Li,et al.  Protective effects of chicken egg yolk antibody (IgY) against experimental Vibrio splendidus infection in the sea cucumber (Apostichopus japonicus). , 2016, Fish & shellfish immunology.

[74]  M. Stiborová,et al.  Effect of chicken antibodies on inflammation in human lung epithelial cell lines. , 2014, Neuro endocrinology letters.

[75]  Y. Kodama,et al.  A novel solution for prevention and treatment of alimentary tract diseases , 2013 .

[76]  H. Terzolo,et al.  IgY-technology: application and trends. , 2006 .

[77]  D. Carlander,et al.  Chicken antibodies: a clinical chemistry perspective. , 1999, Upsala journal of medical sciences.